Privacy Policy
Predictive analytics for intelligent biopharma production
Cytomos® believes in affordable biopharmaceutical therapies serving the world's growing population made possible by intelligent bioprocessing
Intelligent bioprocessing requires novel, integrated and scalable process analytical technologies
Cytomos® Dielectric Spectroscopy (CDS™) is a full-stack, single-cell resolution analysis technology, spanning integrated sensors through to machine learning enhanced algorithms
CDS™ | The Dark Side of Spectroscopy
Different wavelengths of light refract at different angles
Different electric field frequencies behave similarly
CDS™ applies an electric field across single cells in suspension measuring 16,000+ frequencies per cell
Different interfaces in and around each cell refract different frequencies, generating a unique CDS™ spectrum per cell
A platform for evaluation & collaboration
Unbiased
Label-free spectroscopy
Predictive analysis potential
Scalable
Single-cell resolution of
cells flowing in suspension
Integrated
Microelectronic sensors can be implemented across production
Identifying cells without labels
Example: Identifying lymphocyte sub-populations within a mixture
(a) Scatterplot view after dimensional reduction
(b) CDS™ spectroscopic output
T-cell lymphoblasts (MOLT-4) identified from a 1:1 mixture with B-cell lymphoblasts (MM1.s) via different CDS™ spectra, confirmed with MM1.s only sample. Each dot in Figure (a) represents a cell identified from an individual CDS™ spectrum. Average spectrum for each gate shown in Figure (b). 12,144 cells measured in 15 mins.
Monitoring manufacturing drift
Example: Identifying subtle differences between T-cell lines
(a) Scatterplot view after dimensional reduction
(b) CDS™ spectroscopic output
T-cell lymphoblasts (MOLT-4 vs Jurkat) differentiated through their intrinsic CDS™ spectra. Each dot in Figure (a) represents a cell identified from an individual CDS™ spectrum. Average spectrum for each identified population shown in Figure (b). 4,103 cells measured in 15 mins.
Latest News
Edinburgh, UK
28 June 2022
£1.6m additional funding secured
This £1.6m funding – led by Archangels, alongside Scottish Enterprise and Old College Capital – will enable the development and qualification of Cytomos Dielectric Spectroscopy (CDS) to move forward at pace and address the biopharma industry’s
unmet needs.
Enabling non-specialists to perform quantitative and qualitative cytometry without typical cell labelling reagents will help unlock multiple markets with very high growth potential. Analysts estimate the value of the global market for single-cell analysis is expected to reach $6.3 billion by 2026.
“On behalf of our Board and employees I would like to thank our investors for their continued support of Cytomos. We now have the growth capital required to advance the development of our novel process analytical technology platform to the next phase of prototype evaluation with our strategic partners. This is an important milestone in the journey to deliver our mission to enable the development and manufacture of life-saving biologic therapies.”
Dr Alan Raymond,
Executive Chairman, Cytomos
Creativity | Collaboration | Delivery
Cytomos® has a strong multi-disciplinary team of biological scientists and engineers dedicated to providing our partners with relevant and actionable information from their bioprocesses
Cytomos Announcements
Edinburgh, UK
8 July 2022
Gordon Sharp
Interim Chief Technology Officer (CTO)
Gordon Sharp has joined the Executive team to lead our excellent Engineering team and continue working closely with the Scientific team. Gordon’s arrival strengthens our market position by bringing 30+ years’ experience in the microelectronic and instrumentation industries to Cytomos. He will lead the complex instrument design programme and strengthen our IP portfolio in collaborations with industrial and academic partners.
Edinburgh, UK
1 August 2022
Dr. Lindsay Fraser
Chief Scientific Officer
Lindsay joins the Executive team to lead our excellent Biology team and direct our scientific programme. The former Head of Technical Services at Symbiosis Pharmaceutical Service has extensive knowledge in the field of regenerative medicine and cellular therapy. Lindsay will build a portfolio of strategic partnerships with biologics industry thought leaders to win trial and adoption of our innovative process analytical technology platform.
Cytomos Limited
13 Melville Street
Edinburgh EH3 7PE
Scotland
Registered in Scotland SC401416
© Cytomos Limited 2021